scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
Company profile
Ticker
SRRK
Exchange
Website
CEO
Nagesh Mahanthappa
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Scholar Rock, Inc. • Scholar Rock Securities Corporation ...
IRS number
823750435
SRRK stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
19 Mar 24
8-K
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
15 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Results of Operations and Financial Condition
7 Nov 23
8-K
Scholar Rock Announces Proposed Public Offering of Common Stock
12 Oct 23
424B5
Prospectus supplement for primary offering
12 Oct 23
424B5
Prospectus supplement for primary offering
11 Oct 23
Latest ownership filings
4
Edward H Myles
21 Feb 24
4
Mo Qatanani
20 Feb 24
4
Caryn Parlavecchio
20 Feb 24
4
Junlin Ho
20 Feb 24
4
Jay T. Backstrom
20 Feb 24
3
Katie Peng
15 Feb 24
SC 13G
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
ARCH Venture Fund VIII, L.P.
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.21 mm | 70.21 mm | 70.21 mm | 70.21 mm | 70.21 mm | 70.21 mm |
Cash burn (monthly) | 13.49 mm | 5.45 mm | 14.56 mm | 13.64 mm | 10.76 mm | 11.40 mm |
Cash used (since last report) | 80.19 mm | 32.38 mm | 86.54 mm | 81.09 mm | 63.95 mm | 67.76 mm |
Cash remaining | -9.98 mm | 37.83 mm | -16.33 mm | -10.88 mm | 6.26 mm | 2.45 mm |
Runway (months of cash) | -0.7 | 6.9 | -1.1 | -0.8 | 0.6 | 0.2 |
Institutional ownership, Q3 2023
98.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 93 |
Opened positions | 15 |
Closed positions | 12 |
Increased positions | 51 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 317.04 bn |
Total shares | 76.58 mm |
Total puts | 2.90 k |
Total calls | 44.70 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Artal International S.C.A. | 10.56 mm | $0.00 |
Artal | 9.06 mm | $64.32 mm |
FMR | 8.01 mm | $56.84 bn |
T. Rowe Price | 7.17 mm | $50.82 bn |
Samsara BioCapital | 5.66 mm | $30.92 mm |
Redmile | 4.73 mm | $33.61 bn |
Samsara BioCapital | 4.60 mm | $32.65 bn |
Polaris Venture Partners VI | 4.05 mm | $0.00 |
BLK Blackrock | 3.48 mm | $24.71 bn |
BLVGF Bellevue | 2.14 mm | $15.18 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Edward H Myles | Common Stock | Sell | Dispose S | No | No | 15.7432 | 4,744 | 74.69 k | 210,976 |
12 Feb 24 | Jay T. Backstrom | Common Stock | Grant | Acquire A | No | No | 0 | 214,285 | 0.00 | 364,285 |
12 Feb 24 | Jay T. Backstrom | Stock Option Common Stock | Grant | Acquire A | No | No | 15.75 | 285,715 | 4.50 mm | 285,715 |
12 Feb 24 | Jing L. Marantz | Common Stock | Grant | Acquire A | No | No | 0 | 72,855 | 0.00 | 72,855 |
12 Feb 24 | Jing L. Marantz | Stock Option Common Stock | Grant | Acquire A | No | No | 15.75 | 97,145 | 1.53 mm | 97,145 |
12 Feb 24 | Tracey Sacco | Common Stock | Grant | Acquire A | No | No | 0 | 49,285 | 0.00 | 49,285 |
12 Feb 24 | Tracey Sacco | Stock Option Common Stock | Grant | Acquire A | No | No | 15.75 | 65,715 | 1.04 mm | 65,715 |
News
Piper Sandler Maintains Overweight on Scholar Rock Holding, Maintains $28 Price Target
26 Mar 24
Truist Securities Reiterates Buy on Scholar Rock Holding, Maintains $20 Price Target
25 Mar 24
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $30 Price Target
19 Mar 24
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
5 Mar 24
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit Of SRK-439 For Healthy Weight Loss Management
6 Feb 24
Press releases
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Mar 24
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Feb 24
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
25 Jan 24
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
23 Jan 24
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 24